Medicine
Brevibloc 100 mg/10 mL injection
Brevibloc 100 mg/10 mL injection is a prescription medicine containing Esmolol for intravenous use, marketed by Baxter Healthcare, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25˚C (77˚F). Excursions permitted to 15˚-30˚C (59˚-86˚F).
Key facts
- Active ingredient (INN)
- Esmolol
- Brand
- Brevibloc
- Strength
- 100 mg/10 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 25 vials of 10 mL, 1 vial of 10 mL
- Marketing authorisation holder
- Baxter Healthcare
- Manufacturers
- Baxter HealthcareHenry Schein
- Origin register
- US FDA, United States
- Storage
- Store at 25˚C (77˚F). Excursions permitted to 15˚-30˚C (59˚-86˚F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C07AB09 Esmolol
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 31 December 1986
- Identifiers
- RxCUI 1736546, 1736547, 979432 +3DailyMed set ID 38a8b23a-fca8-45f4-a09a-9c8b21f522cd, 595cc3d5-1306-4828-aefa-5595219ffd62NDC 0404-9825, 10019-115Application NDA019386
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 25 vial in 1 carton / 10 mL in 1 vial | 10019-115-01 | Baxter Healthcare | 31 December 1986 |
| 1 vial, single-dose in 1 bag / 10 mL in 1 vial, single-dose | 0404-9825-10 | Henry Schein | 9 January 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 31 December 1986 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Esmolol 100 mg/10 mL injection.
Other strengths and forms of Esmolol
Clinical summary
Esmolol is a beta-adrenergic blocker indicated for the short-term treatment of control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia, among other approved uses. MedsAcross supplies Esmolol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about EsmololFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- BREVIBLOC prescribing information (Baxter Healthcare) · U.S. National Library of Medicine, DailyMed
Need Brevibloc 100 mg/10 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.